Recursion (NASDAQ: RXRX) posts new investor deck for JP Morgan Healthcare event

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. furnished an updated investor presentation dated January 12, 2026. The presentation will be used at the JP Morgan Healthcare Conference and in other investor meetings, giving an overview of the company and its strategy. It is attached as Exhibit 99.1 to this report and is provided under Regulation FD, meaning it is being shared to keep all investors equally informed. The materials are expressly treated as "furnished" rather than "filed," which limits their exposure to certain Exchange Act liabilities and affects how they may be incorporated by reference into other regulatory documents.

0001601830FALSE00016018302026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

RECURSION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40323

46-4099738

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

41 S Rio Grande Street

Salt Lake City, UT 84101

(Address of principal executive offices) (Zip code)

(385) 269 - 0203

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share			RXRX			Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) released an updated investor presentation. The investor presentation will be used at the JP Morgan Healthcare Conference and from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Description
99.1			Investor Presentation of Recursion Pharmaceuticals, Inc. dated January 12, 2026.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January 12, 2026.

			RECURSION PHARMACEUTICALS, INC.
			By:			/s/ Nathan Hatfield
						Nathan Hatfield
						Chief Legal Officer

FAQ

What did Recursion Pharmaceuticals (RXRX) disclose in this 8-K?

Recursion Pharmaceuticals (RXRX) disclosed that it released an updated investor presentation dated January 12, 2026, attached as Exhibit 99.1.

How will Recursion Pharmaceuticals use the new investor presentation?

The updated investor presentation will be used at the JP Morgan Healthcare Conference and from time to time in meetings with investors.

Is the Recursion (RXRX) investor presentation considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibit 99.1, is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.

Where can investors find the updated Recursion Pharmaceuticals presentation?

Investors can review the updated presentation in Exhibit 99.1 to this 8-K report filed by Recursion Pharmaceuticals, Inc.

What exhibits are included with this Recursion Pharmaceuticals 8-K?

The 8-K includes Exhibit 99.1, the investor presentation dated January 12, 2026, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Why does Recursion use Item 7.01 Regulation FD Disclosure for this update?

Item 7.01 is used to provide Regulation FD disclosures so all investors receive the same information, here via the updated investor presentation.